More than half of patients in the U.S. treated for depression may be eligible for psilocybin-assisted therapy if the FDA approves, according to researchers at Emory University, the University of Wisconsin-Madison and UC Berkeley.
The researchers determined that between 56% and 62% of patients currently receiving treatment for depression—5.1 to 5.6 million individuals—could qualify for psilocybin therapy, if approved.
Citation: Syed F. Rab, Charles L. Raison, and Elliot Marseille. An Estimate of the Number of People with Clinical Depression Eligible for Psilocybin-Assisted Therapy in the United States. 24 September 2024. Psychedelics (Genomic Press, New York) (open-access)
Thumbnail image credit: A. Angelica, DALL E